A Clinical Trial Evaluating TG4050 in Head and Neck Cancer (NCT04183166)
A Randomized Phase I/II Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy.
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Jacksonville — Jacksonville, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Hôpital Saint André - CHU de Bordeaux — Bordeaux,
- Hôpital de la Timone — Marseille,
- Institut Curie — Paris,
- IUCT Toulouse — Toulouse,
- Institut Gustave Roussy — Villejuif,
- Hospital Universitari Vall d Hebrón — Barcelona,
- Institut Català d Oncologia - Hospital Duran i Reynals — Barcelona,
- Hospital Clínico San Carlos — Madrid,
- Hospital Universitario La Paz — Madrid,
- Hospital Regional Universitario de Málaga - Hospital Civil — Málaga,
- Complejo Hospitalario Universitario de Santiago — Santiago de Compostela,
- NHS Clatterbridge Cancer Center — Liverpool,
- Aintree University Hospital NHS Fondation Trust — Liverpool,
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab Plus Olaparib in LA-HNSCC — Indianapolis, Indiana
- TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC — Tampa, Florida
- HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer — Dallas, Texas
- MicroRNA Markers in Head and Neck Cancers — Aurora, Colorado
- A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer — La Jolla, California
Explore by condition: All Squamous Cell Carcinoma of Head and Neck clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.